AN2-502998 (oral)

About AN2 Therapeutics

AN2 Therapeutics is a public biotech company focused on discovering and developing novel boron-based small molecule therapeutics for serious infectious diseases with high unmet need. Its most advanced candidate, AN2-502998, is an oral therapy in Phase 2/3 development for chronic Chagas disease, a life-threatening parasitic infection. The company's strategy leverages a proven boron chemistry platform, pioneered at Anacor, to create potent and selective inhibitors against challenging targets, with a pipeline that also includes programs for melioidosis and oncology. AN2 is led by industry veterans with a strong track record in neglected disease drug development and partnership building.

Therapeutic Areas